Angiogenesis characterizes embryonic development, but also occurs in adulthood in physiological situations such as adaptation to muscle exercise, and in pathological conditions like cancer. Major advances have been made in understanding the molecular mechanisms responsible for vasculogenesis and angiogenesis, largely due to the use of “knock-out mice”, i.e. mice in which the gene coding for the protein under investigation has been inactivated. Interestingly, the same growth factors and their receptors are equally involved in the different aspects of vasculogenesis and angiogenesis during development and in adulthood. This review aims to describe in detail their respective roles and how interactions between them lead to a newly formed vessel.
Antonelli-OrlidgeASaundersKB: An activated form of transforming growth factor beta is produced by cocultures of endothelial cells and pericytes. Proc Natl Acad Sci86: 4544–4548, USA1989.
2.
AsaharaTMuroharaT: Isolation of putative progenitor endothelial cells for angiogenesis. Science275: 964–967, 1997.
3.
BairdA: Angiogenesis in health and disease, Richmond, Berlex Biosciences, 75–88, 2000.
4.
BastagliLLazzarottoT: Presence of basic fibroblast growth factor in cultured rat cardiomyocytes and its release in culture medium. Ann N Y Acad Sci752: 417–421, 1995.
CantarellaGLempereurL: Nerve growth factor-endothelial cell interaction leads to angiogenesis in vitro and in vivo. FASEB J16: 1307–1309, 2002.
7.
CarmelietPFerreiraV: Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature380: 435–439, 1996.
8.
CarmelietP: Developmental biology. One cell, two fates. Nature408: 43–45, 2000.
9.
ComerotaAJThromRC: Naked plasmid DNA encoding fibroblast growth factor type 1 for the treatment of end-stage unreconstructible lower extremity ischemia: preliminary results of a phase I trialJ Vasc Surg35: 930–936, 2002.
10.
CrawfordSEStellmachV: Thrombospondin-1 is a major activator of TGF-beta1 in vivo. Cell93: 1159–1170, 1998.
11.
D'AmorePASmithSR: Growth factor effects on cells of the vascular wall: a survey. Growth Factors8: 61–75, 1993.
12.
DavisSAldrichTH: Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell87: 1161–1169, 1996.
13.
DicksonMCMartinJS: Defective haematopoiesis and vasculogenesis in transforming growth factor-beta 1 knock out mice. Development121: 1845–1854, 1995.
14.
DrakeCJBrandtSJ: TAL1/SCL is expressed in endothelial progenitor cells/angioblasts and defines a dorsal-to-ventral gradient of vasculogenesis. Dev Biol192: 17–30, 1997.
15.
DumontDJYamaguchiTP: Tek, a novel tyrosine kinase gene located on mouse chromosome 4, is expressed in endothelial cells and their presumptive precursors. Oncogene7: 1471–1480, 1992.
16.
DumontDJGradwohlG: Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo. Genes Dev8: 1897–1909, 1994.
17.
FerraraNCarver-MooreK: Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature380: 439–442, 1996.
18.
FerraraN: Angiogenesis in health disease, Richmond, Berlex Biosciences, 47–73, 2000.
19.
FolkmanJD'AmorePA: Blood vessel formation: what is its molecular basis?Cell87: 1153–1155, 1996.
20.
HanahanD: Signaling vascular morphogenesis and maintenance. Science277: 48–50, 1997.
21.
HiratsukaSMinowa: Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc Natl Acad Sci95: 9349–9354, USA1998.
22.
HirshiKKD'AmorePA: Pericytes in the microvasculature. Cardiovasc. Res32: 687–698, 1996.
23.
HolmgrenLGlaserA: Angiogenesis during human extraembryonic development involves the spatiotemporal control of PDGF ligand and receptor gene expression. Development113: 749–754, 1991.
24.
JeltschMKaipainenA: Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science276: 1423–1425, 1997.
25.
JohnsonDWBergJN: Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Na. Genet13: 189–195, 1996.
26.
LarssonJGoumansMJ: Abnormal angiogenesis but intact haematopoietic potential in TGF-beta type I receptor-deficient mice. Embo J20: 1663–1673, 2001.
27.
MattotVPourtierA: La morphogénèse de l'arbre vasculaire. de la compréhension des mécanismes moléculaires aux perspectives thérapeutiques. Med Sci14: 437–447, 1998.
28.
McAallisterKAGroggKM: Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet8: 345–351, 1994.
29.
MukouyamaYSShinD: Sensory nerves determine the pattern of arterial differentiation and blood vessel branching in the skin. Cell109: 693–705, 2002.
30.
MungerJSHuangX: The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell96: 319–328, 1999.
OshimaMOshimaH: TGF-beta receptor type II deficiency results in defects of yolk sac haematopoiesis and vasculogenesis. Dev Biol179: 297–302, 1996.
33.
PatanSAlvarezMJ: Intussusceptive microvascular growth: a common alternative to capillary sprouting. Arch Histo l Cytol55: 65–75, 1992.
34.
PooleTJFinkelsteinEBCoxCM: The role of FGF and VEGF in angioblast induction and migration during vascular development. Developmental Dynamics220: 1–17, 2001.
35.
RisauW: Mechanisms of angiogenesis. Nature386: 671–674, 1997.
36.
RubensteinJLKimJ: Anti-VEGF antibody treatment of glioblastoma prologs survival but results in increased vascular cooption. Neoplasia2: 306–314, 2000.
37.
SatoTNTosawaY: Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature376: 70–74, 1995.
38.
ShalabyFRossantJ: Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature376: 62–66, 1995.
39.
SuhDY: Understanding angiogenesis and its clinical applications. Ann Clin Lab Sci30: 227–238, 2000.
40.
SuriCJonesPF: Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell87: 1171–1180, 1996.
41.
ValenzuelaDMGriffithsJA: Angiopoietins 3 and 4: diverging gene counterparts in mice and humans. Proc Natl Acad Sci96: 1904–1909, USA1999.
42.
VikkulaMBoonLM: Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2. Cell87: 1181–1190, 1996.
43.
WangHUChenZFAndersonDJ: Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4. Cell93: 741–753, 1998.
44.
YamashitaJItohH: Flk1-positive cells derived from embryonic stem cells serve as vascular progenitors. Nature408: 92–96, 2000.
